Travere Therapeutics (NASDAQ:TVTX) Earns “Overweight” Rating from Cantor Fitzgerald

Travere Therapeutics (NASDAQ:TVTX)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report issued on Friday,Benzinga reports.

A number of other research analysts have also recently issued reports on TVTX. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Evercore ISI upped their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Finally, Scotiabank upped their price target on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.77.

Travere Therapeutics Stock Down 6.8 %

Shares of NASDAQ:TVTX opened at $21.98 on Friday. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -5.36 and a beta of 0.72. The company has a 50 day moving average of $19.68 and a 200-day moving average of $16.63. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics has a one year low of $5.12 and a one year high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The firm had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. On average, sell-side analysts forecast that Travere Therapeutics will post -1.4 earnings per share for the current year.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Peter Heerma sold 1,584 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total transaction of $30,000.96. Following the transaction, the insider now directly owns 106,374 shares in the company, valued at $2,014,723.56. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Sandra Calvin sold 54,244 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at approximately $1,360,250. This trade represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 218,425 shares of company stock valued at $4,674,259 over the last three months. 3.75% of the stock is currently owned by insiders.

Institutional Trading of Travere Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in shares of Travere Therapeutics during the fourth quarter valued at $31,000. Sterling Capital Management LLC grew its stake in shares of Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after purchasing an additional 2,115 shares during the period. R Squared Ltd purchased a new position in shares of Travere Therapeutics during the 4th quarter valued at about $53,000. CWM LLC lifted its position in shares of Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares in the last quarter. Finally, Gen Wealth Partners Inc purchased a new position in shares of Travere Therapeutics during the 4th quarter valued at about $73,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.